Pliant Therapeutics Inc (NASDAQ: PLRX) kicked off on Tuesday, up 1.12% from the previous trading day, before settling in for the closing price of $13.34. Over the past 52 weeks, PLRX has traded in a range of $10.22-$19.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -32.88% over the last five years. While this was happening, its average annual earnings per share was recorded -32.31%. With a float of $53.76 million, this company’s outstanding shares have now reached $60.85 million.
The firm has a total of 158 workers. Let’s measure their productivity. In terms of profitability, gross margin is 66.96%, operating margin of -4588.47%, and the pretax margin is -4166.96%.
Pliant Therapeutics Inc (PLRX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Pliant Therapeutics Inc is 11.66%, while institutional ownership is 96.20%. The most recent insider transaction that took place on Jul 10 ’24, was worth 142,408. In this transaction Chief Medical Officer of this company sold 12,319 shares at a rate of $11.56, taking the stock ownership to the 213,052 shares. Before that another transaction happened on Jul 10 ’24, when Company’s Chief Business Officer sold 9,900 for $11.56, making the entire transaction worth $114,444. This insider now owns 227,494 shares in total.
Pliant Therapeutics Inc (PLRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.31% per share during the next fiscal year.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Take a look at Pliant Therapeutics Inc’s (PLRX) current performance indicators. Last quarter, stock had a quick ratio of 10.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.34, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -4.02 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Analysing the last 5-days average volume posted by the [Pliant Therapeutics Inc, PLRX], we can find that recorded value of 1.09 million was better than the volume posted last year of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 26.26%. Additionally, its Average True Range was 0.84.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 55.61%, which indicates a significant increase from 34.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.70% in the past 14 days, which was lower than the 59.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.07, while its 200-day Moving Average is $13.13. Now, the first resistance to watch is $13.63. This is followed by the second major resistance level at $13.78. The third major resistance level sits at $14.00. If the price goes on to break the first support level at $13.26, it is likely to go to the next support level at $13.04. Should the price break the second support level, the third support level stands at $12.89.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
The company with the Market Capitalisation of 820.92 million has total of 60,854K Shares Outstanding. Its annual sales at the moment are 1,580 K in contrast with the sum of -161,340 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -57,760 K.
